Efficacy of 1V270-micelles in murine CT26 cancer model. Efficacy of 100, 200 or 300 nmol (5.5, 11, or 16.5 mg/kg) 1V270-micelles, vehicle-micelles or 200 nmol R848 in mice with CT26 tumors (n = 9). Treatments were given every fourth day for a total of five treatments. (A) Dosing schedule. (B) Tumor growth following treatment. (C) Survival of mice following treatment. (D) Complete responders from A to C and 8 tumor-naïve mice were challenged with 3 × 105 CT26 cancer cells on the contralateral flank and considered having rejected rechallenge if no tumor had grown for 60 d following rechallenge. Statistical analyses were Kruskal-Wallis with Dunn's multiple comparisons test (B) and log-rank (Mantel-Cox) test with correction for multiple comparisons (C). Tumor growth inhibition (TGI) and statistical comparisons to untreated in (B) was done on the last day where all mice were alive (day 16).
